- Canada
- /
- Medical Equipment
- /
- TSXV:MDX
MedX Health Third Quarter 2024 Earnings: CA$0.003 loss per share (vs CA$0.007 loss in 3Q 2023)
MedX Health (CVE:MDX) Third Quarter 2024 Results
Key Financial Results
- Revenue: CA$90.6k (down 19% from 3Q 2023).
- Net loss: CA$694.0k (loss narrowed by 49% from 3Q 2023).
- CA$0.003 loss per share (improved from CA$0.007 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
MedX Health shares are up 8.3% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 7 warning signs with MedX Health (at least 5 which are a bit concerning), and understanding these should be part of your investment process.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSXV:MDX
MedX Health
Develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, Europe, and internationally.
Medium-low with weak fundamentals.